Grant programme, Supply Chain innovation for Offshore Renewable Energy (SCORE), recently awarded 4C Offshore a grant for £22,000 to develop an innovative web delivery system for its vast amount of insights into the offshore sector.
Consort Medical company Bespak has won a significant development contract with a major global player for its autoinjector technology for drug delivery.
GW Pharmaceuticals in Cambridge has won a key European approval for a cannabis-based drug to fight Dravet’s syndrome – a rare and lethal form of childhood epilepsy resistant to current treatments.
Bicycle Therapeutics has raised £20 million ($32m) equity financing for the clinical development of therapeutic bicycle drug candidates in oncology.
Domainex in Cambridge and Auspherix Pty in Sydney have joined forces to develop new drugs to treat antibiotic-resistant bacterial infections.
UK personalised medicines enabler Horizon Discovery Group has clinched another big money deal with a top 10 pharmaceutical business working to beat cancer.
BioSilta Ltd, based in Cambridge UK, has tied up with Nasdaq-quoted power player Sigma-Aldrich to commercialise crucial technology for scientific researchers.
A new bedside blood test using Cambridge UK technology has been lauded following successful clinical trials with patients at the Queen Elizabeth Hospital, Birmingham.
Full-year results ahead of market expectations failed to boost Cambridge UK medical technology company Tristel’s early morning share price – it actually fell 1p to 73.50 at one stage.
Instruments that can help patients become their own clinicians – and in their own home – have been made possible by technology from Cambridge Consultants.
Cambridge UK medical technology business Vectura Group plc has earned a milestone payment of €1.5 million following marketing clearance for novel inhaler technology in Portugal.
Biotechnology has shaken up the business environment, creating new ways of thinking and a model for open innovation that is being adopted by other industries, according to Miranda Weston-Smith speaking ahead of a gamechanging event in the Cambridge UK life science and technology cluster.
An investment of £2.98m has been raised by Intelligent Fingerprinting, a Norwich company developing ground-breaking technology that detects drug use through fingerprint sweat analysis.
Cambridge-based charity DNAdigest has spun out social enterprise Nucleobase to develop Open Source platforms to support efficient data access and secure knowledge sharing for genomics research.
Acacia Pharma, the Cambridge UK medical technology business, has stepped up plans to commercialise a novel therapy to counter nausea and vomiting after surgery.
Cambridge UK medical technology specialist Horizon Discovery has secured a knockout piece of business in Austria.
- Smart injection pen rewrites script for diabetics
- Cambridge claims £15m for scientist training boom
- Millions for young scientists to lead bioscience revolution
- Hot money on a Horizon Mayfair monopoly
- Sareum in psoriasis drug breakthrough
- Consort Medical paying £233m for Aesica
- Horizon takes world lead with $48m Sage Labs acquisition
- Horizon triggers US bonanza with $1.2m biopharma deal
- Millions spent on new Cambridge cancer lab
- Horizon hunts down acquisition targets
- Cambridge cash helps Cancer Research spin-out raise £4m
- Expedeon grows globally with Santander cash
- Kymab wins patent battle with Regeneron
- Hauser and Horizon back Axol with near £1m new cash
- Thumbs up for European drug rehab study
- Cambridge duo lead biopharma revolution
Page 1 of 65